INTERPACE BIOSCIENCES FILES 8-K ON FINANCIALS
Ticker: IDXG · Form: 8-K · Filed: Nov 6, 2024 · CIK: 1054102
| Field | Detail |
|---|---|
| Company | Interpace Biosciences, Inc. (IDXG) |
| Form Type | 8-K |
| Filed Date | Nov 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations
TL;DR
INTERPACE BIOSCIENCES (INPC) filed an 8-K on Nov 4th covering financials & operations. Check it out.
AI Summary
On November 4, 2024, INTERPACE BIOSCIENCES, INC. filed an 8-K report detailing events related to its financial condition and operations. The filing includes financial statements and exhibits, with the earliest reported event date being November 4, 2024. The company, formerly known as Interpace Diagnostics Group, Inc., is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing provides crucial updates on INTERPACE BIOSCIENCES, INC.'s financial condition and operational results, which are essential for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial statements and exhibits, not indicating any immediate significant operational or financial distress.
Key Players & Entities
- INTERPACE BIOSCIENCES, INC. (company) — Registrant
- November 4, 2024 (date) — Earliest event reported
- Interpace Diagnostics Group, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- 22-2919486 (tax_id) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition, and to provide Financial Statements and Exhibits for INTERPACE BIOSCIENCES, INC.
What is the earliest event date reported in this filing?
The earliest event date reported in this filing is November 4, 2024.
What were INTERPACE BIOSCIENCES, INC.'s former company names?
INTERPACE BIOSCIENCES, INC. was formerly known as Interpace Diagnostics Group, Inc., PDI INC, and PROFESSIONAL DETAILING INC.
In which state is INTERPACE BIOSCIENCES, INC. incorporated?
INTERPACE BIOSCIENCES, INC. is incorporated in Delaware.
What is the company's fiscal year end?
The company's fiscal year end is December 31.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-11-06 16:46:06
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 86KB
- 0001493152-24-043851.txt ( ) — 303KB
- idxg-20241104.xsd (EX-101.SCH) — 3KB
- idxg-20241104_lab.xml (EX-101.LAB) — 33KB
- idxg-20241104_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2024 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Waterview Plaza , Suite 310 2001 Route 46 , Parsippany , NJ 07054 (Address, including zip code, of Principal Executive Offices) (855) 776-6419 Registrant's telephone number, including area code Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered None N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02 Results of Operations and Financial Condition. On November 4, 2024, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2024. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release, dated November 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Interpace Biosciences, Inc. By: /s/ Thomas W. Burnell Name: Thomas W. Burnell Title: President and Chief Executive Officer Date: November 6, 2024